Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Boundless Bio, Inc. Common Stock (BOLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BOLD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -24.09% | Avg. Invested days 5 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 32.34M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 88807 | Beta - | 52 Weeks Range 1.42 - 13.72 | Updated Date 04/2/2025 |
52 Weeks Range 1.42 - 13.72 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.85 |
Earnings Date
Report Date 2025-03-27 | When - | Estimate -0.785 | Actual -0.74 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -27.23% | Return on Equity (TTM) -48.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -72147043 | Price to Sales(TTM) - |
Enterprise Value -72147043 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 22300000 | Shares Floating 14189913 |
Shares Outstanding 22300000 | Shares Floating 14189913 | ||
Percent Insiders 11.44 | Percent Institutions 74.52 |
Analyst Ratings
Rating 4 | Target Price 18.33 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Boundless Bio, Inc. Common Stock
Company Overview
History and Background
Boundless Bio, Inc. is a clinical-stage oncology company focused on developing innovative therapies targeting extrachromosomal DNA (ecDNA) biology. Founded in 2018, the company is based in San Diego, California.
Core Business Areas
- ecDNA-Directed Therapies: Develop therapies that target ecDNA, a circular form of DNA found in cancer cells that drives tumor growth and resistance to treatment.
Leadership and Structure
The company is led by a team of experienced biotechnology executives and scientists. Details regarding the exact leadership team and organizational structure can be found on their official website or regulatory filings.
Top Products and Market Share
Key Offerings
- BBI-350: BBI-350 is a Chk1 inhibitor designed to selectively kill cancer cells harboring ecDNA. It is currently in clinical trials. Specific market share or revenue data is not yet available as it is still under development. Competitors include other companies developing Chk1 inhibitors and other novel cancer therapies, such as Merck, Eli Lilly, and AstraZeneca.
Market Dynamics
Industry Overview
The oncology market is a large and rapidly growing market driven by an increasing incidence of cancer and advancements in treatment. The development of targeted therapies, including those focused on specific genetic drivers of cancer, is a key trend.
Positioning
Boundless Bio is positioned as a leader in the emerging field of ecDNA-directed therapies. Its focus on a novel target differentiates it from many other oncology companies.
Total Addressable Market (TAM)
The TAM for ecDNA-directed therapies is potentially large, as ecDNA is found in many types of cancer. An estimate would depend on the clinical success of ecDNA-targeting compounds, but could reasonably be in the tens of billions of dollars if successful. Boundless Bio is positioned to capture a significant portion of this TAM if its therapies prove effective.
Upturn SWOT Analysis
Strengths
- Novel therapeutic target (ecDNA)
- Experienced management team
- Strong intellectual property position
- Clinical-stage pipeline
Weaknesses
- Early stage of development
- High risk of clinical trial failure
- Reliance on single therapeutic approach
- Limited financial resources compared to larger pharma companies
Opportunities
- Expansion of pipeline to other ecDNA-driven cancers
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Potential for breakthrough therapy designation
Threats
- Clinical trial failures
- Competition from other oncology companies
- Regulatory hurdles
- Changes in the competitive landscape of oncology treatments
Competitors and Market Share
Key Competitors
- MRK
- LLY
- AZN
Competitive Landscape
Boundless Bio's competitive advantage lies in its novel approach to targeting ecDNA. However, it faces competition from larger pharmaceutical companies with more established oncology portfolios.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the expansion of their pipeline and clinical development milestones.
Future Projections: Future growth depends on clinical trial success and securing additional funding. Analyst estimates are available from various financial data providers.
Recent Initiatives: Recent initiatives include advancing BBI-350 through clinical trials and exploring additional ecDNA targets.
Summary
Boundless Bio is a clinical-stage biotechnology company focused on a novel target, ecDNA. Its innovative approach offers potential in the oncology space, but it faces significant risks associated with clinical development. The company's success hinges on positive clinical trial results and securing sufficient funding. They need to monitor competition and adapt to changes in the oncology treatment landscape.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
LLY
Eli Lilly and Company
LLY
Eli Lilly and Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
Sources and Disclaimers
Data Sources:
- Boundless Bio's website
- SEC filings (10-K, 10-Q)
- Analyst reports
- Press releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary depending on the source. The AI-based rating is based on publicly available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Boundless Bio, Inc. Common Stock
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2024-03-28 | CEO, President & Director Mr. Zachary Hornby | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://boundlessbio.com |
Full time employees 64 | Website https://boundlessbio.com | ||
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.